# Results: Phase 1 Interim Data

## Patient characteristics

- As of April 2020, 25 patients have been enrolled with DLGUSC and 4 with MCL.
- Baseline characteristics of patients enrolled up to 6 April 2020:

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>DLGUSC (n=25)</th>
<th>MCL (n=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years</td>
<td>64 (43–79)</td>
<td>59 (57–66)</td>
</tr>
<tr>
<td>Sex, n (%)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>21 (84.0)</td>
<td>4 (100.0)</td>
</tr>
<tr>
<td>Female</td>
<td>4 (16.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>ECOG score, n (%)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>14 (56.0)</td>
<td>1 (25.0)</td>
</tr>
<tr>
<td>1</td>
<td>11 (44.0)</td>
<td>3 (75.0)</td>
</tr>
</tbody>
</table>

## Results: Phase 1 Interim Data

### Safety and tolerability

- No more than 1 DLT in 6 patients and at least 1 patient has a documented PR or complete response (CR).
- This is an open-label, single-arm dose escalation and dose expansion trial.
- Evaluate the safety and tolerability of Lonca with ibrutinib in patients with R/R DLBCL or MCL.

### Preclinical

- Preclinically, the combination of Lonca and ibrutinib has shown synergy and activity in phase 1 and 2 trials.

### Immunogenicity

- All measures for unconjugated warhead SG3199 were below the lower limit of quantitation (LLOQ).
- Slower clearance, increased exposure, and modest accumulation suggest good exposure coverage throughout the dosing interval (Figure 2).

### PK profile of Lonca

- Slower clearance, increased exposure, and modest accumulation suggest good exposure coverage throughout the dosing interval (Table 2).

### TEAEs

- TEAEs are shown by grade in Table 3.

### Results

- Lonca has shown single-agent activity in phase 1 and 2 trials.
- Here, we present interim phase 1 data from the phase 1/2 trial of Lonca combined with ibrutinib in patients with R/R DLBCL or MCL.
- The combination has a manageable safety and tolerability profile at the MTD of Lonca 60 µg/kg with ibrutinib 560 mg/day.
- In patients with DLBCL treated with Lonca 60 µg/kg, ORR is 37.7% with a CR of 6.2%.
- PK profiles demonstrate good exposure throughout the dosing interval.
- This study is continuing to enroll patients.